CoChat

A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis – Study design and rationale of HM-TRIA-201 study

Abdelmalek, Manal F., Suzuki, Ayako, Sanchez, Willian, Lawitz, Eric, Filozof, Claudia, Cho, Hyungjin, Baek, Eunhye, Choi, JaeDuk, Baek, Seungjae · 2023 · Contemporary Clinical Trials
Cited by 51

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Non-alcoholic steatohepatitis (NASH) is a multifactorial disease with an increasing prevalence worldwide due to the obesity pandemic. HM15211 (efocipegtrutide), a novel, long-acting glucagon-like peptide-1/glucagon/glucose-dependent insulinotropic polypeptide triple incretin agonist has shown promising efficacy in in vitro, preclinical rodent models of NASH and phase 1 studies with manageable toxicity. Though liver biopsy is recommended for grading and staging of NASH, its invasive nature necessitates innovative approaches in clinical trials that decrease the burden of patients otherwise subjected to this invasive procedure. We report an innovative study design of phase 2 study of HM15211. METHODS: HM-TRIA-201 is a multicenter, randomized, double-blind, 52-week, placebo-controlled, parallel-group adaptive design study of 217 patients with biopsy-proven NASH. The primary endpoint is the proportion of patients with complete resolution of steatohepatitis (defined as Non-alcoholic fatty liver disease Activity Score of 0-1 for inflammation, 0 for ballooning, and any other value for steatosis) on overall histopathological reading and no worsening of liver fibrosis on NASH Clinical Research Network fibrosis score. An interim analysis is planned after 15 patients/group complete 26 weeks of treatment, after which one HM15211 dose group will be discontinued based on safety and efficacy risk-to-benefit analysis; patients of the dropped dosing arm will be re-randomized into 2 remaining HM15211 groups. CONCLUSION: The adaptive design study of HM15211 minimizes the number of patients to be exposed to a liver biopsy while optimizing the sample size of patients exposed to safe and effective doses of HM15211 to inform ideal dose for further clinical development in NASH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cct.2023.107176

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 13

  1. Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology., 67, 328, 10.1002/hep.29367 · DOI · Paper page
  2. Noureddin, 2018, Pathogenesis of NASH: the impact of multiple pathways, Curr. Hepatol. Rep., 17, 350, 10.1007/s11901-018-0425-7 · DOI · Paper page
  3. Kabarra, 2021, Nonalcoholic steatohepatitis: global impact and clinical consequences, Endocr. Conn., 10, R240, 10.1530/EC-21-0048 · DOI
  4. Harrison, 2018, NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, Lancet., 391, 1174, 10.1016/S0140-6736(18)30474-4 · DOI · Paper page
  5. Armstrong, 2013, Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial, BMJ Open, 3, 10.1136/bmjopen-2013-003995 · DOI · Paper page
  6. Choi, 2020, 1830-P: therapeutic effect of a novel long-acting GLP-1/GIP/glucagon triple agonist (HM15211) in CDHFD-induced NASH and Fibrosis mice, Diabetes., 69, 10.2337/db20-1830-P · DOI
  7. Kleiner, 2005, Nonalcoholic steatohepatitis clinical research network, design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology., 41, 1313, 10.1002/hep.20701 · DOI · Paper page
  8. Filozof, 2017, Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: facilitating development approaches for an emerging epidemic, Hepatol. Commun., 1, 577, 10.1002/hep4.1079 · DOI · Paper page
  9. Guirguis, 2021, Emerging therapies for the treatment of nonalcoholic steatohepatitis: a systematic review, Pharmacotherapy., 41, 315, 10.1002/phar.2489 · DOI
  10. Kim, 2021, 656-P: Antifibrotic potential of a novel long-acting glucagon/GIP/GLP-1 triple agonist (HM15211) in preclinical models of Fibrosis, Diabetes., 70, 656, 10.2337/db21-656-P · doi:10.2337/db21-656-p
  11. Sanyal, 2011, Endpoints and clinical trial design for nonalcoholic steatohepatitis, Hepatology., 54, 344, 10.1002/hep.24376 · DOI · Paper page
  12. Friedman, 2016, Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR phase 2b study design, Contemp. Clin. Trial., 47, 356, 10.1016/j.cct.2016.02.012 · DOI · Paper page
  13. Pedrosa, 2020, A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: study design of the TANDEM trial, Contemp. Clin. Trial., 88, 10.1016/j.cct.2019.105889 · DOI · Paper page

Cited by

See all 51

Metadata

Authors
Abdelmalek, M. F., Suzuki, A., Sanchez, W., Lawitz, E., Filozof, C., Cho, H., Baek, E., Choi, J., & Baek, S.
Venue
Contemporary Clinical Trials
Publisher
Elsevier BV
Published
2023-07
Volume
130
Pages
107176
ISSN
1551-7144 (ISSN-L)
OpenAlex
W4362603506
Cited by
51
References
16
FWCI
8.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis – Study design and rationale of HM-TRIA-201 study. https://app.cochat.ai/papers/10.1016/j.cct.2023.107176
The paper
Abdelmalek, M. F., Suzuki, A., Sanchez, W., Lawitz, E., Filozof, C., Cho, H., Baek, E., Choi, J., & Baek, S. (2023). A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis – Study design and rationale of HM-TRIA-201 study. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2023.107176

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.